Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS
Clinical Case Reports, 2024
Plaas M., Brazovskaja A., Kisand K., Tserel L., Peterson P.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Immunological & Inflammatory Diseases | Pathophysiology | Plasma | O Olink Target 96 |
Abstract
We identified two CRSwNP patients who had previously failed treatment with an anti‐IL‐4/IL‐13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti‐IL‐17 antibody (secukinumab). Anti‐IL‐17 antibody secukinumab was superior in reducing their NPS and SNOT‐22 values compared to dupilumab. IL‐17 could be a promising target for non‐type II and mixed endotype CRS treatment.